Clean Science & Technology has announced its audited standalone and consolidated financial results for the fourth quarter and financial year ended March 31, 2026. The Board of Directors, at their meeting held on May 14, 2026, approved the financial results and recommended a final dividend of ₹4 per equity share of face value ₹1 each for FY26, subject to shareholder approval at the ensuing Annual General Meeting. The statutory auditors, Price Waterhouse Chartered Accountants LLP, issued an unmodified audit opinion on both standalone and consolidated financial results. In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company also confirmed the upload of the audio recording of its Q4 FY26 Earnings Conference Call, held on May 14, 2026, on its official website.

Standalone Financial Performance

On a standalone basis, the company reported revenue from operations of ₹815 crore for FY26, a decline from ₹922 crore in FY25. Standalone profit after tax (PAT) for the year stood at ₹251 crore, a decrease of 14% from ₹292 crore in the previous year. Despite the revenue decline, standalone EBITDA margins remained resilient at 44.3% for FY26, compared to 44.0% in FY25. For the quarter ended March 31, 2026, standalone revenue from operations was ₹197 crore, lower than ₹245 crore in Q4 FY25, while standalone PAT stood at ₹58.10 crore compared to ₹78.60 crore in the corresponding quarter of the previous year. On a sequential basis, standalone revenue improved by 6% from ₹185 crore in Q3 FY26, while EBITDA rose by 22% quarter-on-quarter. EBITDA margins recovered to 44.7% in Q4 FY26 from 42.59% in Q4 FY25. During Q4 FY26, the Executive Directors voluntarily elected to forgo a substantial portion of their performance bonus entitlement for FY26, resulting in a reversal of earlier provisions and lower employee benefits expense for the quarter.

The following table summarises the key standalone and consolidated financial metrics:

Consolidated Financial Performance

On a consolidated basis, the company reported revenue from operations of ₹957 crore for FY26, a marginal decrease from ₹967 crore in FY25. Consolidated PAT for the year stood at ₹230 crore, a decline of 13% from ₹266 crore in FY25. Consolidated EBITDA stood at ₹355 crore with margins at 37.7%, compared to ₹388 crore and 40.8% in the prior year. The consolidated results include the financial performance of four wholly owned subsidiaries: Clean Fino-Chem Limited, Clean Science Private Limited, Clean Aromatics Private Limited, and Clean Organics Private Limited. The Group is exclusively engaged in the manufacturing of organic chemicals, constituting a single primary operating segment as per Ind AS 108.

The standalone statement of assets and liabilities as at March 31, 2026 reflects total assets of ₹17,839.51 million, compared to ₹16,048.84 million as at March 31, 2025. Total equity stood at ₹16,456.44 million, with other equity at ₹16,350.16 million. On a consolidated basis, total assets were ₹17,829.00 million as at March 31, 2026, against ₹16,077.60 million in the prior year, with total equity at ₹15,837.71 million.

Earnings Per Share

The standalone basic earnings per share (EPS) for FY26 stood at ₹23.64, compared to ₹27.51 in FY25. Diluted EPS was ₹23.63 for FY26 against ₹27.50 in FY25. For Q4 FY26, standalone basic EPS was ₹5.47 and diluted EPS was ₹5.46. On a consolidated basis, basic EPS for FY26 was ₹21.61 and diluted EPS was ₹21.60, compared to ₹24.88 each in FY25.

Corporate Actions and Other Developments

The Board recommended a final dividend of ₹4 per equity share of face value ₹1 each for FY26, implying a total payout ratio of 25% for the year. The book closure and dividend payment date will be determined later. The Board also approved an additional investment of ₹200 crore in one or more tranches in Clean Fino-Chem Limited, a wholly owned subsidiary. The company incurred a total capex of approximately ₹220 crore during FY26, primarily towards investment in its subsidiary. During FY26, 10,040 equity shares of ₹1 each fully paid-up were allotted upon exercise of vested stock options pursuant to the Company's Employee Stock Option Scheme, 2021 (ESOP 2021). The Board also approved the re-appointment of M/s CNK JBMS & Associates as Internal Auditors and M/s Dhananjay V. Joshi & Associates as Cost Auditors, both for FY 2026-27.

Q4 FY26 Earnings Conference Call

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Clean Science & Technology confirmed the upload of the audio recording of its Q4 FY26 Earnings Conference Call, held on May 14, 2026, on the company's official website. The recording is accessible at the weblink published on the company's website. The submission was made by Ruchita Vij, Company Secretary and Compliance Officer.

Source: Company/INE227W01023

Clean Science & Technology 's Nomination and Remuneration Committee (NRC) approved the grant of 5,000 Employee Stock Options (ESOPs) to eligible employees on Thursday, May 14, 2026. The grant was made under the Clean Science and Technology Limited Employee Stock Option Scheme 2021 (CSTL ESOS 2021), in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Share Based Employee Benefit and Sweat Equity) Regulations, 2021. The company disclosed this development to both BSE Limited and the National Stock Exchange of India Limited.

Key Details of the ESOP Grant

The following table summarises the core parameters of the stock option grant approved by the NRC:

Vesting Schedule

The 5,000 stock options are subject to a four-year vesting schedule. The vesting is structured progressively, with a larger portion vesting in the final year. The detailed vesting schedule is as follows:

The exercise period for each tranche is 1 (one) year from the respective date of vesting. This means eligible employees must exercise their vested options within one year of each vesting date.

Scheme Administration and Eligibility

The CSTL ESOS 2021 is administered by the Nomination and Remuneration Committee. The grant of stock options is based on the eligibility criteria as specified under the CSTL ESOS 2021 scheme. The company has confirmed that no options have been exercised, lapsed, or cancelled in connection with this grant, and there are no variations to the terms of the options at this stage.

The intimation was signed by Ruchita Vij, Company Secretary and Compliance Officer of Clean Science & Technology, and submitted to the stock exchanges on May 14, 2026.